Interpretable machine learning for predicting residual cancer burden following neoadjuvant therapy in HER2 positive breast cancer: A real-world study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Accurate early prediction of response to neoadjuvant therapy (NAT) in HER2-positive breast cancer could support pre-treatment risk stratification. We conducted a retrospective real-world study of 692 patients treated between November 2018 and May 2025 at a tertiary center to develop interpretable machine-learning models for pre-treatment prediction of residual cancer burden (RCB; favorable: RCB 0–I vs. poor: RCB II–III). Least absolute shrinkage and selection operator identified nine routinely available predictors, and ten algorithms were trained with 10-fold cross-validation and grid search. Among them, a gradient boosting machine (GBM) achieved the best discrimination in the independent test set (AUC 0.796) with superior calibration and net clinical benefit. SHAP highlighted HER2 status, hormone-receptor status and clinical nodal stage as the strongest contributors, consistent with biological expectations. We implemented a Shiny web application for research and educational use. In a propensity score–matched comparison of trastuzumab–pertuzumab versus trastuzumab– pyrotinib regimens, no significant difference in achieving favorable RCB was observed. This interpretable GBM model shows potential for pre-treatment risk stratification in patients with HER2-positive breast cancer; however, its current predictive performance does not support stand-alone clinical decision-making.
Source: Scientific Reports
Institutions: Union Hospital, Fujian Medical University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7236627930
